Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription

Articles published in Cancer Lett

Retrieve available abstracts of 51 articles:
HTML format

Single Articles

    December 2022
  1. SU S, You S, Wang Y, Tamukong P, et al
    PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer by increasing immune infiltration.
    Cancer Lett. 2022 Dec 9:216034. doi: 10.1016/j.canlet.2022.216034.
    PubMed     Abstract available

    November 2022
  2. FENG J, Xi Z, Jiang X, Li Y, et al
    Saikosaponin a enhances Docetaxel efficacy by selectively inducing death of dormant prostate cancer cells through excessive autophagy.
    Cancer Lett. 2022 Nov 25:216011. doi: 10.1016/j.canlet.2022.216011.
    PubMed     Abstract available

  3. LACOMBE L, Hovington H, Brisson H, Mehdi S, et al
    UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways.
    Cancer Lett. 2022 Nov 4:215994. doi: 10.1016/j.canlet.2022.215994.
    PubMed     Abstract available

    October 2022
  4. CHUA CW, Kruithof-de Julio M
    Exploring prostate cancer in the post-genomic era.
    Cancer Lett. 2022;553:215992.
    PubMed     Abstract available

    September 2022
  5. LIU J, Dong L, Zhu Y, Dong B, et al
    Prostate cancer treatment - China's perspective.
    Cancer Lett. 2022 Sep 23:215927. doi: 10.1016/j.canlet.2022.215927.
    PubMed     Abstract available

  6. FERGUSON AM, Rubin MA
    Lineage plasticity in prostate cancer: Looking beyond intrinsic alterations.
    Cancer Lett. 2022 Sep 5:215901. doi: 10.1016/j.canlet.2022.215901.
    PubMed     Abstract available

    August 2022
  7. JIAO J, Zhang J, Li Z, Wen W, et al
    Prostate specific membrane antigen positron emission tomography in primary prostate cancer diagnosis: First-line imaging is afoot.
    Cancer Lett. 2022 Aug 23:215883. doi: 10.1016/j.canlet.2022.215883.
    PubMed     Abstract available

    July 2022
  8. ZHANG J, Li S, Zhang J, Zhang W, et al
    Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING/MAVS signaling pathway.
    Cancer Lett. 2022 Jul 19:215829. doi: 10.1016/j.canlet.2022.215829.
    PubMed     Abstract available

    June 2022
  9. CHUA CW, Kruithof-de Julio M
    Featuring the guest editors for the Special Issue on Prostate Cancer, Cancer Letters.
    Cancer Lett. 2022;544:215807.

  10. MAI CW, Chin KY, Foong LC, Pang KL, et al
    Modeling prostate cancer: What does it take to build an ideal tumor model?
    Cancer Lett. 2022;543:215794.
    PubMed     Abstract available

    May 2022
  11. LORENZONI M, De Felice D, Beccaceci G, Di Donato G, et al
    ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3beta dependent Nkx3.1 degradation.
    Cancer Lett. 2022;534:215612.
    PubMed     Abstract available

    April 2022
    Precision intervention for prostate cancer: Re-evaluating who is at risk.
    Cancer Lett. 2022 Apr 28:215709. doi: 10.1016/j.canlet.2022.215709.
    PubMed     Abstract available

    March 2022
  13. FONTANA F, Anselmi M, Limonta P
    Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy.
    Cancer Lett. 2022 Mar 8:215619. doi: 10.1016/j.canlet.2022.215619.
    PubMed     Abstract available

    February 2022
  14. DENG W, Zhou X, Zhu K, Chen R, et al
    Novel circular RNA circ_0086722 drives tumor progression by regulating the miR-339-5p/STAT5A axis in prostate cancer.
    Cancer Lett. 2022;533:215606.
    PubMed     Abstract available

  15. MIRO C, Di Giovanni A, Murolo M, Cicatiello AG, et al
    Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer.
    Cancer Lett. 2022 Feb 5:215581. doi: 10.1016/j.canlet.2022.215581.
    PubMed     Abstract available

  16. LOWDER D, Rizwan K, McColl C, Paparella A, et al
    Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics.
    Cancer Lett. 2022 Feb 2. pii: S0304-3835(22)00044.
    PubMed     Abstract available

  17. CHEN H, Miao Y, Bian A, Ye J, et al
    A novel small-molecule activator of unfolded protein response suppresses castration-resistant prostate cancer growth.
    Cancer Lett. 2022;532:215580.
    PubMed     Abstract available

    January 2022
  18. BAEK DS, Kim YJ, Vergara S, Conard A, et al
    A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo.
    Cancer Lett. 2022;525:97-107.
    PubMed     Abstract available

  19. CROWLEY L, Shen MM
    Heterogeneity and complexity of the prostate epithelium: New findings from single-cell RNA sequencing studies.
    Cancer Lett. 2022;525:108-114.
    PubMed     Abstract available

  20. CHALLASIVAKANAKA S, Vickman RE, Kakarla M, Hayward SW, et al
    Fibroblast heterogeneity in prostate carcinogenesis.
    Cancer Lett. 2022;525:76-83.
    PubMed     Abstract available

  21. KANG J, La Manna F, Bonollo F, Sampson N, et al
    Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer.
    Cancer Lett. 2022 Jan 17. pii: S0304-3835(22)00023.
    PubMed     Abstract available

  22. QIAN C, Li D, Chen Y
    ETS factors in prostate cancer.
    Cancer Lett. 2022 Jan 13. pii: S0304-3835(22)00017.
    PubMed     Abstract available

  23. HERNANDEZ I, Cohen M
    Linking cell-surface GRP78 to cancer: From basic research to clinical value of GRP78 antibodies.
    Cancer Lett. 2022;524:1-14.
    PubMed     Abstract available

    December 2021
  24. BERNASOCCHI T, Theurillat JP
    SPOP-mutant prostate cancer: Translating fundamental biology into patient care.
    Cancer Lett. 2021;529:11-18.
    PubMed     Abstract available

  25. MARHOLD M, Kramer G, Krainer M, Le Magnen C, et al
    The prostate cancer landscape in Europe: Current challenges, future opportunities.
    Cancer Lett. 2021 Dec 1. pii: S0304-3835(21)00606.
    PubMed     Abstract available

  26. CHIODELLI P, Coltrini D, Turati M, Cerasuolo M, et al
    FGFR blockade by pemigatinib treats naive and castration resistant prostate cancer.
    Cancer Lett. 2021;526:217-224.
    PubMed     Abstract available

  27. CHAKRABORTY S, Utter MB, Frias MA, Foster DA, et al
    Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin.
    Cancer Lett. 2021;522:164-170.
    PubMed     Abstract available

    November 2021
  28. SHI M, Wang Y, Lin D, Wang Y, et al
    Patient-derived xenograft models of neuroendocrine prostate cancer.
    Cancer Lett. 2021;525:160-169.
    PubMed     Abstract available

  29. SU S, Cao J, Meng X, Liu R, et al
    Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases.
    Cancer Lett. 2021 Nov 6. pii: S0304-3835(21)00558.
    PubMed     Abstract available

  30. HAQ S, Sarodaya N, Karapurkar JK, Suresh B, et al
    CYLD destabilizes NoxO1 protein by promoting ubiquitination and regulates prostate cancer progression.
    Cancer Lett. 2021;525:146-157.
    PubMed     Abstract available

    October 2021
  31. WANG C, Zhang Y, Gao WQ
    The evolving role of immune cells in prostate cancer.
    Cancer Lett. 2021 Oct 26. pii: S0304-3835(21)00545.
    PubMed     Abstract available

    Experimental challenges to modeling prostate cancer heterogeneity.
    Cancer Lett. 2021;524:194-205.
    PubMed     Abstract available

  33. TOIVANEN R, Porter LH, Li Z, Clouston D, et al
    Hidden clues in prostate cancer - Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification.
    Cancer Lett. 2021;524:182-192.
    PubMed     Abstract available

  34. WANG S, Chao F, Zhang C, Han D, et al
    Circular RNA circPFKP promotes cell proliferation by activating IMPDH2 in prostate cancer.
    Cancer Lett. 2021;524:109-120.
    PubMed     Abstract available

  35. MUGONI V, Ciani Y, Nardella C, Demichelis F, et al
    Circulating RNAs in prostate cancer patients.
    Cancer Lett. 2021;524:57-69.
    PubMed     Abstract available

  36. CACKOWSKI FC, Heath EI
    Prostate cancer dormancy and recurrence.
    Cancer Lett. 2021 Oct 5. pii: S0304-3835(21)00498.
    PubMed     Abstract available

  37. KANAGASABAI T, Li G, Shen TH, Gladoun N, et al
    MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway.
    Cancer Lett. 2021 Oct 2. pii: S0304-3835(21)00502.
    PubMed     Abstract available

    September 2021
  38. TIAN P, Zhong M, Wei GH
    Mechanistic insights into genetic susceptibility to prostate cancer.
    Cancer Lett. 2021 Sep 21. pii: S0304-3835(21)00472.
    PubMed     Abstract available

  39. RUIZ DE PORRAS V, Font A, Aytes A
    Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives.
    Cancer Lett. 2021 Sep 10. pii: S0304-3835(21)00430.
    PubMed     Abstract available

    August 2021
  40. WANG Y, Yu J
    Dissecting multiple roles of SUMOylation in prostate cancer.
    Cancer Lett. 2021;521:88-97.
    PubMed     Abstract available

  41. LI Q, Ye L, Zhang X, Wang M, et al
    Corrigendum to "FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/beta-catenin signaling" [Cancer Lett. 402 (2017) 166-176].
    Cancer Lett. 2021 Aug 3. pii: S0304-3835(21)00383.

    July 2021
  42. CAMPBELL KJ, Leung HY
    Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance.
    Cancer Lett. 2021 Jul 31. pii: S0304-3835(21)00378.
    PubMed     Abstract available

  43. GAO Y, Liu Y, Liu Y, Peng Y, et al
    UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications.
    Cancer Lett. 2021;520:172-183.
    PubMed     Abstract available

  44. LIANG J, Wang L, Poluben L, Nouri M, et al
    Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.
    Cancer Lett. 2021 Jul 10. pii: S0304-3835(21)00340.
    PubMed     Abstract available

    June 2021
  45. YAMADA Y, Beltran H
    The treatment landscape of metastatic prostate cancer.
    Cancer Lett. 2021 Jun 18. pii: S0304-3835(21)00295.
    PubMed     Abstract available

  46. JAMROZE A, Chatta G, Tang DG
    Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
    Cancer Lett. 2021;518:1-9.
    PubMed     Abstract available

    May 2021
  47. HOU Z, Huang S, Li Z
    Androgens in prostate cancer: A tale that never ends.
    Cancer Lett. 2021;516:1-12.
    PubMed     Abstract available

  48. FREELAND J, Crowell PD, Giafaglione JM, Boutros PC, et al
    Aging of the progenitor cells that initiate prostate cancer.
    Cancer Lett. 2021;515:28-35.
    PubMed     Abstract available

  49. HUANG SB, Thapa D, Munoz AR, Hussain SS, et al
    Androgen deprivation-induced elevated nuclear SIRT1 promotes prostate tumor cell survival by reactivation of AR signaling.
    Cancer Lett. 2021;505:24-36.
    PubMed     Abstract available

    February 2021
  50. LLOPIZ D, Ruiz M, Silva L, Reparaz D, et al
    Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.
    Cancer Lett. 2021;499:279-289.
    PubMed     Abstract available

    January 2021
  51. SONG J, Yu J, Jeong LS, Lee SK, et al
    A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells.
    Cancer Lett. 2021;497:54-65.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.